CERO THERAPEUTICS HOLDINGS, INC.

Cero Therapeutics Holdings, Inc. filed an 8-K with the SEC on January 5, 2024, under SPAC ticker PBAX, marking the completion of the business combination between Phoenix Biotech Acquisition Corp and Cero Therapeutics. Phoenix Biotech Acquisition Corp, sponsored by Phoenix Biotech Sponsor LLC, conducted its initial public offering in 2021 with a stated focus on the biotechnology and life sciences sector. Cero Therapeutics is a clinical-stage biopharmaceutical company advancing chimeric engulfment receptor T-cell therapies for oncology indications. The combined public entity now operates as Cero Therapeutics Holdings, Inc. Sign up at SpacDesk for complete filing histories, deal timelines, and real-time SPAC data across the full market.